BioResource emails and phones are not monitored on a regular basis and our ability to respond may be affected by our remote working and/or the impact of a wider COVID-19 infection.

If you have an urgent query, please email either nbr@bioresource.nihr.ac.uk or ibd@bioresource.nihr.ac.uk and we will endeavour to respond as soon as possible.

Apologies for the inconvenience this may cause. Thank you in advance for your understanding and cooperation.

Information for recruiting sites and Stage 2 studies investigators

Recruiting sites *** UPDATE 07/09/20 ***

The NIHR BioResource –Research Tissue Bank, of which the IBD BioResource is a part, will be lifting the temporary halt to non-COVID-19 recruitment activities with effect from the 7th September 2020.

Please do not re-start recruitment until you receive new instructions, material and a confirmation from ibd@bioresource.nihr.ac.uk . 

Site’s recruiting team will need to receive new packaging labels and instructions and possibly sample tubes, before any re-start of recruitment and sample taking activities. This will be coordinated by the central IBD coordination team based in Cambridge. 

Stage 2 Studies

Apart from research studies through online questionnaires, other recall activities will be on hold until further notice.

Information for patients

Pertinent summaries of Public Health England advice and information can be found at Crohn’s and Colitis UK 

Covid19 risk stratification for patients with Crohn’s and colitis

You will be aware of the concerns around the immunosuppressant medications used to treat IBD and the risk this causes during the coronavirus outbreak. It is important that you follow guidance from the Department of Health, and any advice from your physician, about your medication. Working with the IBD Registry and British Society of Gastroenterology we want to help patients to understand their risk, and through the IBD BioResource learn how the medication you are taking may affect susceptibility to COVID-19 and the course of infection with the virus.

To further understand the disease we have also established a COVID BioResource, recruiting volunteers with and without COVID-19, who are helping us with COVID-related research. In coming weeks we may get in touch with you to ask if you would like to contribute to such research. This may involve the completion of questionnaires, including on your health and any stress or anxiety you are experiencing.

In the meantime, to help you ‘risk-stratify’ yourself accurately, can I please recommend that you visit a tool that has been specifically set up to do this? It will be helpful whether or not you are on immunosuppressant medication. The main thing is to help you understand whether or not you are in a high vs medium vs low risk group and what precautions you need to take. We may also, if you are willing, be able to link some of the data entered to help our analysis re the safety of these drugs.

The link is here:
https://ibdregistry.org.uk/covid-19/

From all at IBD BioResource we wish you well in these difficult times

Dr Miles Parkes
IBD BioResource Chief Investigator

Last Updated on